{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:05:21Z","timestamp":1782831921466,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Big Data"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Triple-negative breast cancer (TNBC) is a relatively aggressive breast cancer subtype due to tumor relapse, drug resistance, and multi-organ metastatic properties. Identifying reliable biomarkers to predict prognosis and precisely guide TNBC immunotherapy is still an unmet clinical need. To address this issue, we successfully constructed a novel 25 machine learning (ML) algorithms-based immune infiltrating cell (IIC) associated signature of TNBC (MLIIC), achieved by multiple transcriptome data of purified immune cells, TNBC cell lines, and TNBC entities. The TSI index was employed to determine IIC-RNAs that were accompanied by an expression pattern of upregulation in immune cells and downregulation in TNBC cells. LassoLR, Boruta, Xgboost, SVM, RF, and Pamr were utilized for further obtaining the optimal IIC-RNAs. Following univariate Cox regression analysis, LassoCox, CoxBoost, and RSF were utilized for the dimensionality reduction of IIC-RNAs from a prognostic perspective. RSF, Ranger, ObliqueRSF, Rpart, CoxPH, SurvivalSVM, CoxBoost, GlmBoost, SuperPC, StepwiseCox, Enet, LassoCox, CForest, Akritas, BlackBoost, PlsRcox, SurvReg, GBM, and CTree were used for determining the most potent MLIIC signature. Consequently, this MLIIC signature was correlated significantly with survival status validated by four independent TNBC cohorts. Also, the MLIIC signature had a superior predictive capability for TNBC prognosis, compared with 148 previously reported signatures. In addition, MLIIC signature scores developed by immunofluorescent staining of tissue arrays from TNBC patients showed a substantial prognostic value. In TNBC immunotherapy, the low MLIIC profile demonstrated significant immune-responsive efficacy in a dataset of multiple cancer types. MLIIC signature could also predict m6A epigenetic regulation which controls T cell homeostasis. Therefore, this well-established MLIIC signature is a robust predictive indicator for TNBC prognosis and the benefit of immunotherapy, thus providing an efficient tool for combating TNBC.<\/jats:p>","DOI":"10.1186\/s40537-023-00809-1","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T17:02:02Z","timestamp":1693069322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Artificial intelligence learning landscape of triple-negative breast cancer uncovers new opportunities for enhancing outcomes and immunotherapy responses"],"prefix":"10.1186","volume":"10","author":[{"given":"Shuyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xisong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"issue":"11","key":"809_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"809_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91\u2013113. https:\/\/doi.org\/10.1038\/s41571-021-00565-2","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"809_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, Zhang L, Hu J, Luo P, Zhang J, Liu Z, Peng Y, Liu Z, Tang L, Cheng Q. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15(1):111. https:\/\/doi.org\/10.1186\/s13045-022-01325-0","journal-title":"J Hematol Oncol"},{"key":"809_CR4","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0200","author":"M Anurag","year":"2022","unstructured":"Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, Vashist TD, Tran Huynh AM, Dou Y, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Dobrolecki LE, Rodriguez H, Robles AI, Hiltke T, Lewis MT, Nangia JR, Nemati Shafaee M, Li S, Hagemann IS, Hoog J, Lim B, Osborne CK, Mani DR, Gillette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, Ellis MJ. Proteogenomic markers of chemotherapy resistance and response in triple negative breast cancer. Cancer Discov. 2022. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0200","journal-title":"Cancer Discov"},{"key":"809_CR5","doi-asserted-by":"publisher","first-page":"108253","DOI":"10.1016\/j.pharmthera.2022.108253","volume":"237","author":"JY So","year":"2022","unstructured":"So JY, Ohm J, Lipkowitz S, Yang L. Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options. Pharmacol Ther. 2022;237:108253. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108253","journal-title":"Pharmacol Ther"},{"key":"809_CR6","doi-asserted-by":"publisher","first-page":"910976","DOI":"10.3389\/fonc.2022.910976","volume":"12","author":"CA Huertas-Caro","year":"2022","unstructured":"Huertas-Caro CA, Ramirez MA, Gonzalez-Torres HJ, Sanabria-Salas MC, Serrano-Gomez SJ. Immune Lymphocyte infiltrate and its Prognostic Value in Triple-Negative breast Cancer. Front Oncol. 2022;12:910976. https:\/\/doi.org\/10.3389\/fonc.2022.910976","journal-title":"Front Oncol"},{"issue":"11","key":"809_CR7","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1016\/j.apsb.2021.02.007","volume":"11","author":"Z Xu","year":"2021","unstructured":"Xu Z, Wang X, Zeng S, Ren X, Yan Y, Gong Z. Applying artificial intelligence for cancer immunotherapy. Acta Pharm Sin B. 2021;11(11):3393\u2013405. https:\/\/doi.org\/10.1016\/j.apsb.2021.02.007","journal-title":"Acta Pharm Sin B"},{"issue":"8","key":"809_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2022.07.006","volume":"40","author":"A Zaitsev","year":"2022","unstructured":"Zaitsev A, Chelushkin M, Dyikanov D, Cheremushkin I, Shpak B, Nomie K, Zyrin V, Nuzhdina E, Lozinsky Y, Zotova A, Degryse S, Kotlov N, Baisangurov A, Shatsky V, Afenteva D, Kuznetsov A, Paul SR, Davies DL, Reeves PM, Lanuti M, Goldberg MF, Tazearslan C, Chasse M, Wang I, Abdou M, Aslanian SM, Andrewes S, Hsieh JJ, Ramachandran A, Lyu Y, Galkin I, Svekolkin V, Cerchietti L, Poznansky MC, Ataullakhanov R, Fowler N, Bagaev A. Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. Cancer Cell. 2022;40(8):879\u2013894e816. https:\/\/doi.org\/10.1016\/j.ccell.2022.07.006","journal-title":"Cancer Cell"},{"issue":"4","key":"809_CR9","doi-asserted-by":"publisher","first-page":"e13409","DOI":"10.1111\/cpr.13409","volume":"56","author":"N Zhang","year":"2023","unstructured":"Zhang N, Zhang H, Liu Z, Dai Z, Wu W, Zhou R, Li S, Wang Z, Liang X, Wen J, Zhang X, Zhang B, Ouyang S, Zhang J, Luo P, Li X, Cheng Q. An artificial intelligence network-guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms. Cell Prolif. 2023;56(4):e13409. https:\/\/doi.org\/10.1111\/cpr.13409","journal-title":"Cell Prolif"},{"key":"809_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac386","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhang N, Wu W, Zhou R, Li S, Wang Z, Dai Z, Zhang L, Liu Z, Zhang J, Luo P, Liu Z, Cheng Q. Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma. Brief Bioinform. 2022. https:\/\/doi.org\/10.1093\/bib\/bbac386","journal-title":"Brief Bioinform"},{"issue":"13","key":"809_CR11","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.7150\/thno.74281","volume":"12","author":"N Zhang","year":"2022","unstructured":"Zhang N, Zhang H, Wu W, Zhou R, Li S, Wang Z, Dai Z, Zhang L, Liu F, Liu Z, Zhang J, Luo P, Liu Z, Cheng Q. Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma. Theranostics. 2022;12(13):5931\u201348. https:\/\/doi.org\/10.7150\/thno.74281","journal-title":"Theranostics"},{"issue":"3","key":"809_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy\u2013analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307\u201315. https:\/\/doi.org\/10.1093\/bioinformatics\/btg405","journal-title":"Bioinformatics"},{"key":"809_CR13","doi-asserted-by":"publisher","unstructured":"Sun J, Zhang Z, Bao S, Yan C, Hou P, Wu N, Su J, Xu L, Zhou M. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer. 2020;8(1). https:\/\/doi.org\/10.1136\/jitc-2019-000110","DOI":"10.1136\/jitc-2019-000110"},{"issue":"5","key":"809_CR14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/bioinformatics\/bti042","volume":"21","author":"I Yanai","year":"2005","unstructured":"Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, Ophir R, Bar-Even A, Horn-Saban S, Safran M, Domany E, Lancet D, Shmueli O. Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics. 2005;21(5):650\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/bti042","journal-title":"Bioinformatics"},{"issue":"7","key":"809_CR15","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. https:\/\/doi.org\/10.1093\/nar\/gkv007","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"809_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","volume":"43","author":"T Hothorn","year":"2003","unstructured":"Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal. 2003;43(2):121\u201337. https:\/\/doi.org\/10.1016\/S0167-9473(02)00225-6","journal-title":"Comput Stat Data Anal"},{"issue":"4","key":"809_CR17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Cancer Genome Atlas Research N, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The Immune Landscape of Cancer. Immunity. 2018;48(4):812\u201330. e814.","journal-title":"Immunity"},{"issue":"8","key":"809_CR18","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340. https:\/\/doi.org\/10.1172\/JCI91190","journal-title":"J Clin Invest"},{"key":"809_CR19","doi-asserted-by":"publisher","unstructured":"Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9(379). https:\/\/doi.org\/10.1126\/scitranslmed.aah3560","DOI":"10.1126\/scitranslmed.aah3560"},{"issue":"1","key":"809_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","volume":"17","author":"Y Senbabaoglu","year":"2016","unstructured":"Senbabaoglu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016;17(1):231. https:\/\/doi.org\/10.1186\/s13059-016-1092-z","journal-title":"Genome Biol"},{"issue":"21","key":"809_CR21","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for Comprehensive Analysis of Tumor-Infiltrating Immune cells. Cancer Res. 2017;77(21):e108\u201310. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0307","journal-title":"Cancer Res"},{"issue":"1","key":"809_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype Relationships and Predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248\u201362. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019","journal-title":"Cell Rep"},{"issue":"1","key":"809_CR23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautes-Fridman C, Fridman WH, de Reynies A. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218. https:\/\/doi.org\/10.1186\/s13059-016-1070-5","journal-title":"Genome Biol"},{"key":"809_CR24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https:\/\/doi.org\/10.1038\/ncomms3612","journal-title":"Nat Commun"},{"issue":"6","key":"809_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004","journal-title":"Cell Syst"},{"issue":"1","key":"809_CR26","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. https:\/\/doi.org\/10.1038\/s41467-019-09234-6","journal-title":"Nat Commun"},{"issue":"Suppl 4","key":"809_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"4","author":"CH Chin","year":"2014","unstructured":"Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 8 Suppl. 2014;4(Suppl 4):11. https:\/\/doi.org\/10.1186\/1752-0509-8-S4-S11","journal-title":"BMC Syst Biol 8 Suppl"},{"issue":"19","key":"809_CR28","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1200\/JCO.2012.44.3762","volume":"31","author":"F Ulloa-Montoya","year":"2013","unstructured":"Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont AM, Vansteenkiste J, Brichard VG. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol. 2013;31(19):2388\u201395. https:\/\/doi.org\/10.1200\/JCO.2012.44.3762","journal-title":"J Clin Oncol"},{"issue":"4","key":"809_CR29","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martin-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017;171(4):934\u2013949e916. https:\/\/doi.org\/10.1016\/j.cell.2017.09.028","journal-title":"Cell"},{"issue":"3","key":"809_CR30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","volume":"168","author":"W Hugo","year":"2017","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell. 2017;168(3):542. https:\/\/doi.org\/10.1016\/j.cell.2017.01.010","journal-title":"Cell"},{"issue":"6257","key":"809_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207\u201311. https:\/\/doi.org\/10.1126\/science.aad0095","journal-title":"Science"},{"issue":"1","key":"809_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/2326-6066.CIR-16-0019","volume":"5","author":"T Nathanson","year":"2017","unstructured":"Nathanson T, Ahuja A, Rubinsteyn A, Aksoy BA, Hellmann MD, Miao D, Van Allen E, Merghoub T, Wolchok JD, Snyder A, Hammerbacher J. Somatic mutations and Neoepitope Homology in Melanomas treated with CTLA-4 blockade. Cancer Immunol Res. 2017;5(1):84\u201391. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0019","journal-title":"Cancer Immunol Res"},{"issue":"7693","key":"809_CR33","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen III, Astarita H, Cubas JL, Jhunjhunwala R, Banchereau S, Yang R, Guan Y, Chalouni Y, Ziai C, Senbabaoglu J, Santoro Y, Sheinson S, Hung D, Giltnane J, Pierce JM, Mesh AA, Lianoglou K, Riegler S, Carano J, Eriksson RAD, Hoglund P, Somarriba M, Halligan L, van der Heijden DL, Loriot MS, Rosenberg Y, Fong JE, Mellman L, Chen I, Green DS, Derleth M, Fine C, Hegde GD, Bourgon PS, Powles R T. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138. https:\/\/doi.org\/10.1038\/nature25501","journal-title":"Nature"},{"issue":"6","key":"809_CR34","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun DA, Hou Y, Bakouny Z, Ficial M, Sant\u2019 Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909\u201318. https:\/\/doi.org\/10.1038\/s41591-020-0839-y","journal-title":"Nat Med"},{"issue":"11","key":"809_CR35","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, Thel H, Hoyos D, Mehta A, Arshad S, Lieb DJ, Drapek LC, Blaszkowsky LS, Giantonio BJ, Weekes CD, Zhu AX, Goyal L, Nipp RD, Dubois JS, Van Seventer EE, Foreman BE, Matlack LE, Ly L, Meurer JA, Hacohen N, Ryan DP, Yeap BY, Corcoran RB, Greenbaum BD, Ting DT, Hong TS. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021;2(11):1124\u201335. https:\/\/doi.org\/10.1038\/s43018-021-00269-7","journal-title":"Nat Cancer"},{"issue":"12","key":"809_CR36","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1158\/1078-0432.CCR-20-4443","volume":"27","author":"T van den Ende","year":"2021","unstructured":"van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, Dings MPG, Bergman J, Haj Mohammad N, Ruurda JP, van Hillegersberg R, Mook S, Nieuwdorp M, de Gruijl TD, Soeratram TTD, Ylstra B, van Grieken NCT, Bijlsma MF, Hulshof M, van Laarhoven HWM. Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: a single-arm phase II feasibility trial (PERFECT). Clin Cancer Res. 2021;27(12):3351\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4443","journal-title":"Clin Cancer Res"},{"issue":"4","key":"809_CR37","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdy049","volume":"29","author":"NJ Birkbak","year":"2018","unstructured":"Birkbak NJ, Li Y, Pathania S, Greene-Colozzi A, Dreze M, Bowman-Colin C, Sztupinszki Z, Krzystanek M, Diossy M, Tung N, Ryan PD, Garber JE, Silver DP, Iglehart JD, Wang ZC, Szuts D, Szallasi Z, Richardson AL. Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers. Ann Oncol. 2018;29(4):903\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdy049","journal-title":"Ann Oncol"},{"issue":"10","key":"809_CR38","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0136-1","journal-title":"Nat Med"},{"issue":"11","key":"809_CR39","doi-asserted-by":"publisher","first-page":"e1195","DOI":"10.1371\/journal.pone.0001195","volume":"2","author":"Y Hoshida","year":"2007","unstructured":"Hoshida Y, Brunet JP, Tamayo P, Golub TR, Mesirov JP. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS ONE. 2007;2(11):e1195. https:\/\/doi.org\/10.1371\/journal.pone.0001195","journal-title":"PLoS ONE"},{"key":"809_CR40","doi-asserted-by":"publisher","unstructured":"Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6). https:\/\/doi.org\/10.1093\/bib\/bbab260","DOI":"10.1093\/bib\/bbab260"},{"issue":"9","key":"809_CR41","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9):e107468. https:\/\/doi.org\/10.1371\/journal.pone.0107468","journal-title":"PLoS ONE"},{"key":"809_CR42","doi-asserted-by":"publisher","unstructured":"Yang C, Zhang H, Chen M, Wang S, Qian R, Zhang L, Huang X, Wang J, Liu Z, Qin W, Wang C, Hang H, Wang H. A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. Elife. 2022;11. https:\/\/doi.org\/10.7554\/eLife.71880","DOI":"10.7554\/eLife.71880"},{"issue":"14","key":"809_CR43","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/bioinformatics\/btt269","volume":"29","author":"K Yang","year":"2013","unstructured":"Yang K, Dinasarapu AR, Reis ES, Deangelis RA, Ricklin D, Subramaniam S, Lambris JD. CMAP: complement map database. Bioinformatics. 2013;29(14):1832\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/btt269","journal-title":"Bioinformatics"},{"issue":"11","key":"809_CR44","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356. https:\/\/doi.org\/10.1101\/gr.239244.118","journal-title":"Genome Res"},{"issue":"7","key":"809_CR45","doi-asserted-by":"publisher","first-page":"616","DOI":"10.5306\/wjco.v13.i7.616","volume":"13","author":"XY Mao","year":"2022","unstructured":"Mao XY, Perez-Losada J, Abad M, Rodriguez-Gonzalez M, Rodriguez CA, Mao JH, Chang H. iCEMIGE: integration of CEll-morphometrics, MIcrobiome, and GEne biomarker signatures for risk stratification in breast cancers. World J Clin Oncol. 2022;13(7):616\u201329. https:\/\/doi.org\/10.5306\/wjco.v13.i7.616","journal-title":"World J Clin Oncol"},{"issue":"5","key":"809_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/14728222.2022.2077188","volume":"26","author":"X Xie","year":"2022","unstructured":"Xie X, Lee J, Iwase T, Kai M, Ueno NT. Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. Expert Opin Ther Targets. 2022;26(5):405\u201325. https:\/\/doi.org\/10.1080\/14728222.2022.2077188","journal-title":"Expert Opin Ther Targets"},{"key":"809_CR47","doi-asserted-by":"publisher","first-page":"779786","DOI":"10.3389\/fonc.2022.779786","volume":"12","author":"Q Tan","year":"2022","unstructured":"Tan Q, Yin S, Zhou D, Chi Y, Man X, Li H. Potential predictive and prognostic value of biomarkers related to Immune checkpoint inhibitor therapy of Triple-Negative breast Cancer. Front Oncol. 2022;12:779786. https:\/\/doi.org\/10.3389\/fonc.2022.779786","journal-title":"Front Oncol"},{"issue":"10","key":"809_CR48","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41575-020-0327-3","volume":"17","author":"G Cammarota","year":"2020","unstructured":"Cammarota G, Ianiro G, Ahern A, Carbone C, Temko A, Claesson MJ, Gasbarrini A, Tortora G. Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nat Rev Gastroenterol Hepatol. 2020;17(10):635\u201348. https:\/\/doi.org\/10.1038\/s41575-020-0327-3","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"809_CR49","doi-asserted-by":"publisher","unstructured":"Fan K, Cheng L, Li L. Artificial intelligence and machine learning methods in predicting anti-cancer drug combination effects. Brief Bioinform. 2021;22(6). https:\/\/doi.org\/10.1093\/bib\/bbab271","DOI":"10.1093\/bib\/bbab271"},{"issue":"6","key":"809_CR50","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10038-006-0394-5","volume":"51","author":"H Sato","year":"2006","unstructured":"Sato H, Miyamoto T, Yogev L, Namiki M, Koh E, Hayashi H, Sasaki Y, Ishikawa M, Lamb DJ, Matsumoto N, Birk OS, Niikawa N, Sengoku K. Polymorphic alleles of the human MEI1 gene are associated with human azoospermia by meiotic arrest. J Hum Genet. 2006;51(6):533\u201340. https:\/\/doi.org\/10.1007\/s10038-006-0394-5","journal-title":"J Hum Genet"},{"issue":"7","key":"809_CR51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/atm-22-981","volume":"10","author":"G Dai","year":"2022","unstructured":"Dai G, Ou J, Wu B. A predictive study of metabolism reprogramming in cervical carcinoma. Ann Transl Med. 2022;10(7):414. https:\/\/doi.org\/10.21037\/atm-22-981","journal-title":"Ann Transl Med"},{"issue":"6","key":"809_CR52","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.chembiol.2018.03.010","volume":"25","author":"L Liang","year":"2018","unstructured":"Liang L, Wang H, Shi H, Li Z, Yao H, Bu Z, Song N, Li C, Xiang D, Zhang Y, Wang J, Hu Y, Xu Q, Ma Y, Cheng Z, Wang Y, Zhao S, Qian J, Chen Y, Fang JY, Xu J. A designed peptide targets two types of modifications of p53 with anti-cancer activity. Cell Chem Biol. 2018;25(6):761\u2013774e765. https:\/\/doi.org\/10.1016\/j.chembiol.2018.03.010","journal-title":"Cell Chem Biol"},{"issue":"1","key":"809_CR53","doi-asserted-by":"publisher","first-page":"12349","DOI":"10.1038\/s41598-022-16575-8","volume":"12","author":"Z Zhong","year":"2022","unstructured":"Zhong Z, Jiang W, Zhang J, Li Z, Fan F. Identification and validation of a novel 16-gene prognostic signature for patients with breast cancer. Sci Rep. 2022;12(1):12349. https:\/\/doi.org\/10.1038\/s41598-022-16575-8","journal-title":"Sci Rep"},{"key":"809_CR54","doi-asserted-by":"publisher","DOI":"10.1097\/SCS.0000000000008904","author":"X Meng","year":"2022","unstructured":"Meng X, Pan B, Zhang Z, Guo P, Wang C, Huang X, Si N, Jiang H. Functional pathway and process Enrichment Analysis of genes Associated with Morphological Abnormalities of the outer ear. J Craniofac Surg. 2022. https:\/\/doi.org\/10.1097\/SCS.0000000000008904","journal-title":"J Craniofac Surg"},{"key":"809_CR55","doi-asserted-by":"publisher","first-page":"102357","DOI":"10.1016\/j.scr.2021.102357","volume":"53","author":"N Si","year":"2021","unstructured":"Si N, Zhang Z, Meng X, Huang X, Wang C, Pan B. Generation of an induced pluripotent stem cell line from a congenital microtia patient with 4p16.1 microduplication involving the long-range enhancer of HMX1. Stem Cell Res. 2021;53:102357. https:\/\/doi.org\/10.1016\/j.scr.2021.102357","journal-title":"Stem Cell Res"},{"issue":"12","key":"809_CR56","doi-asserted-by":"publisher","first-page":"e0226212","DOI":"10.1371\/journal.pone.0226212","volume":"14","author":"S Nagel","year":"2019","unstructured":"Nagel S, Scherr M, MacLeod RAF, Pommerenke C, Koeppel M, Meyer C, Kaufmann M, Dallmann I, Drexler HG. NKL homeobox gene activities in normal and malignant myeloid cells. PLoS ONE. 2019;14(12):e0226212. https:\/\/doi.org\/10.1371\/journal.pone.0226212","journal-title":"PLoS ONE"},{"key":"809_CR57","doi-asserted-by":"publisher","first-page":"104439","DOI":"10.1016\/j.yexmp.2020.104439","volume":"115","author":"M Mohebi","year":"2020","unstructured":"Mohebi M, Ghafouri-Fard S, Modarressi MH, Dashti S, Zekri A, Kholghi-Oskooei V, Taheri M. Expression analysis of vimentin and the related lncRNA network in breast cancer. Exp Mol Pathol. 2020;115:104439. https:\/\/doi.org\/10.1016\/j.yexmp.2020.104439","journal-title":"Exp Mol Pathol"},{"issue":"4","key":"809_CR58","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.3892\/mmr.2018.9404","volume":"18","author":"S Natarajan","year":"2018","unstructured":"Natarajan S, Sumantran VN, Ranganathan M, Madheswaran S. Microarray and pattern miner analysis of AXL and VIM gene networks in MDAMB231 cells. Mol Med Rep. 2018;18(4):4147\u201355. https:\/\/doi.org\/10.3892\/mmr.2018.9404","journal-title":"Mol Med Rep"},{"issue":"8","key":"809_CR59","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djab004","volume":"113","author":"LA Emens","year":"2021","unstructured":"Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Dieras V, Iwata H, Barrios CH, Nechaeva M, Nguyen-Duc A, Chui SY, Husain A, Winer EP, Adams S, Schmid P. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative breast Cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst. 2021;113(8):1005\u201316. https:\/\/doi.org\/10.1093\/jnci\/djab004","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"809_CR60","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11427-020-1714-8","volume":"64","author":"SY Wu","year":"2021","unstructured":"Wu SY, Wang H, Shao ZM, Jiang YZ. Triple-negative breast cancer: new treatment strategies in the era of precision medicine. Sci China Life Sci. 2021;64(3):372\u201388. https:\/\/doi.org\/10.1007\/s11427-020-1714-8","journal-title":"Sci China Life Sci"},{"issue":"7","key":"809_CR61","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1158\/0008-5472.CAN-18-2965","volume":"79","author":"Q Lan","year":"2019","unstructured":"Lan Q, Liu PY, Haase J, Bell JL, Huttelmaier S, Liu T. The critical role of RNA m(6)a methylation in Cancer. Cancer Res. 2019;79(7):1285\u201392. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2965","journal-title":"Cancer Res"},{"issue":"7667","key":"809_CR62","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature23450","volume":"548","author":"HB Li","year":"2017","unstructured":"Li HB, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, Bailis W, Cao G, Kroehling L, Chen Y, Wang G, Broughton JP, Chen YG, Kluger Y, Simon MD, Chang HY, Yin Z, Flavell RA. M(6)a mRNA methylation controls T cell homeostasis by targeting the IL-7\/STAT5\/SOCS pathways. Nature. 2017;548(7667):338\u201342. https:\/\/doi.org\/10.1038\/nature23450","journal-title":"Nature"}],"container-title":["Journal of Big Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40537-023-00809-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40537-023-00809-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40537-023-00809-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T22:38:11Z","timestamp":1700433491000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalofbigdata.springeropen.com\/articles\/10.1186\/s40537-023-00809-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["809"],"URL":"https:\/\/doi.org\/10.1186\/s40537-023-00809-1","relation":{},"ISSN":["2196-1115"],"issn-type":[{"value":"2196-1115","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,26]]},"assertion":[{"value":"21 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics of the study was approved. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}